228 related articles for article (PubMed ID: 18519729)
21. Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry.
Dorlo TP; Hillebrand MJ; Rosing H; Eggelte TA; de Vries PJ; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Apr; 865(1-2):55-62. PubMed ID: 18325856
[TBL] [Abstract][Full Text] [Related]
22. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.
Dorlo TP; Balasegaram M; Beijnen JH; de Vries PJ
J Antimicrob Chemother; 2012 Nov; 67(11):2576-97. PubMed ID: 22833634
[TBL] [Abstract][Full Text] [Related]
23. Anti-leishmanial activity of a topical miltefosine gel in experimental models of New World cutaneous leishmaniasis.
Neira LF; Mantilla JC; Escobar P
J Antimicrob Chemother; 2019 Jun; 74(6):1634-1641. PubMed ID: 30815688
[TBL] [Abstract][Full Text] [Related]
24. Oral miltefosine to treat new world cutaneous leishmaniasis.
Soto J; Toledo JT
Lancet Infect Dis; 2007 Jan; 7(1):7. PubMed ID: 17182338
[No Abstract] [Full Text] [Related]
25. Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection.
Kip AE; Rosing H; Hillebrand MJ; Blesson S; Mengesha B; Diro E; Hailu A; Schellens JH; Beijnen JH; Dorlo TP
Antimicrob Agents Chemother; 2016 Apr; 60(4):2081-9. PubMed ID: 26787691
[TBL] [Abstract][Full Text] [Related]
26. Cutaneous Leishmaniasis Treated with Miltefosine: A Case Series of 10 Paediatric Patients.
Ollech A; Solomon M; Horev A; Reiss-Huss S; Ben-Amitai D; Zvulunov A; Friedland R; Atar-Snir V; Pessach-Molcho V; Barzilai A; Greenberger S
Acta Derm Venereol; 2020 Nov; 100(18):adv00322. PubMed ID: 33205828
[TBL] [Abstract][Full Text] [Related]
27. Cutaneous Leishmaniasis Treated with Miltefosine: A Case Series of 10 Paediatric Patients.
Ollech A; Solomon M; Horev A; Reiss-Huss S; Ben-Amitai D; Zvulunov A; Friedland R; Atar-Snir V; Molho-Pessach V; Barzilai A; Greenberger S
Acta Derm Venereol; 2020 Oct; 100(18):adv00322. PubMed ID: 33074340
[TBL] [Abstract][Full Text] [Related]
28. Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India.
Ramesh V; Singh R; Avishek K; Verma A; Deep DK; Verma S; Salotra P
PLoS Negl Trop Dis; 2015; 9(10):e0004093. PubMed ID: 26492039
[TBL] [Abstract][Full Text] [Related]
29. Miltefosine for new world cutaneous leishmaniasis.
Soto J; Arana BA; Toledo J; Rizzo N; Vega JC; Diaz A; Luz M; Gutierrez P; Arboleda M; Berman JD; Junge K; Engel J; Sindermann H
Clin Infect Dis; 2004 May; 38(9):1266-72. PubMed ID: 15127339
[TBL] [Abstract][Full Text] [Related]
30. Treatment of New World cutaneous leishmaniasis with miltefosine.
Soto J; Berman J
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S34-40. PubMed ID: 16930649
[TBL] [Abstract][Full Text] [Related]
31. Investigation of anti-leishmanial efficacy of miltefosine and ketoconazole loaded on nanoniosomes.
Nazari-Vanani R; Vais RD; Sharifi F; Sattarahmady N; Karimian K; Motazedian MH; Heli H
Acta Trop; 2018 Sep; 185():69-76. PubMed ID: 29733808
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the Ability of Miltefosine Associated with Topical GM-CSF in Modulating the Immune Response of Patients with Cutaneous Leishmaniasis.
Peixoto F; Nascimento MT; Costa R; Silva J; Renard G; Guimarães LH; Penna G; Barral-Netto M; Carvalho LP; Machado PRL; Carvalho EM
J Immunol Res; 2020; 2020():2789859. PubMed ID: 32851099
[TBL] [Abstract][Full Text] [Related]
33. An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis.
Palić S; Beijnen JH; Dorlo TPC
Int J Antimicrob Agents; 2022 Jan; 59(1):106459. PubMed ID: 34695563
[TBL] [Abstract][Full Text] [Related]
34. Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine.
Dorlo TP; Balasegaram M; Lima MA; de Vries PJ; Beijnen JH; Huitema AD
J Antimicrob Chemother; 2012 Aug; 67(8):1996-2004. PubMed ID: 22577099
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of miltefosine treatment in Leishmania amazonensis-infected BALB/c mice.
Godinho JL; Simas-Rodrigues C; Silva R; Ürmenyi TP; de Souza W; Rodrigues JC
Int J Antimicrob Agents; 2012 Apr; 39(4):326-31. PubMed ID: 22226653
[TBL] [Abstract][Full Text] [Related]
36. LC-coupled ESI MS for quantification of miltefosine in human and hamster plasma.
Jaiswal S; Sharma A; Shukla M; Lal J
Bioanalysis; 2016 Mar; 8(6):533-45. PubMed ID: 26915470
[TBL] [Abstract][Full Text] [Related]
37. Severe post-kala-azar dermal leishmaniasis successfully treated with miltefosine in an Ethiopian HIV patient.
Abongomera C; Battaglioli T; Adera C; Ritmeijer K
Int J Infect Dis; 2019 Apr; 81():221-224. PubMed ID: 30790722
[TBL] [Abstract][Full Text] [Related]
38. Resolution of cutaneous old world and new world leishmaniasis after oral miltefosine treatment.
Tappe D; Müller A; Stich A
Am J Trop Med Hyg; 2010 Jan; 82(1):1-3. PubMed ID: 20064985
[No Abstract] [Full Text] [Related]
39. [Comparative study between oral miltefosine and parenteral N-metil glucamine antimoniate for the treatment of experimental leishmaniasis caused Leishmania (Leishmania) amazonensis].
Costa Filho AV; Lucas IC; Sampaio RN
Rev Soc Bras Med Trop; 2008; 41(4):424-7. PubMed ID: 18853022
[TBL] [Abstract][Full Text] [Related]
40. Direct comparison of the efficacy and safety of oral treatments with oleylphosphocholine (OlPC) and miltefosine in a mouse model of L. major cutaneous leishmaniasis.
Fortin A; Caridha DP; Leed S; Ngundam F; Sena J; Bosschaerts T; Parriott S; Hickman MR; Hudson TH; Grogl M
PLoS Negl Trop Dis; 2014 Sep; 8(9):e3144. PubMed ID: 25210745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
